Oisín Biotechnologies ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself. We have recently successfully launched our first subsidiary, Oisin Oncology, focusing in combating multiple cancers.
Interview with Stephen Hilbert
We cover the exciting scientific progress at Oisín, targeting senescent cells (dubbed ‘zombie cells’) to help them to die properly, rejuvenation therapy vs traditional approaches to combating disease, Oisín’s potential for aiding astronauts survive high levels of radiation in space, funding for the research and therapy/drug development and specifically Stephen’s background in corporate development in helping raise capital for Oisín and it’s research.
Are we close to achieving Robust Mouse Rejuvenation?
According to Aubrey de Grey we are about 5-6 years away from robust mouse rejuvenation (RBR) subject to the kind of funding SENS has received this year and the previous year (2017-2018). There has been progress in developing certain therapies .
Specifically, the goal of RBR is this:
- Make normal, healthy two-year old mice (expected to live one more year) live three further years.
- The type of mice: The ideal mouse to trail on is one that doesn’t naturally have a certain kind of congenital disease (that might on average only live 1.5 or 2 years) – because increasing their lifespan might only be a sign that you have solved their particular congenital disease.
- Number of extra years: Consistently increasing mouse lifespan for an extra two years on top of their normal three year lifespans – essentially tripling their remaining lifespan.
- When to begin the treatment: Don’t start treating the mice until they are already 2 years old – at a time where they would normally be 2 thirds of the way though their life (at or past middle age) and they would have one more year to live.
Why not start treating the mice earlier? The goal is to produce sufficiently dramatic results in a laboratory to convince the main-stream gerontology community such that they would willingly publicly endorse the idea that it is not impossible, but indeed it is only a matter of time before rejuvenation therapy will work in humans – that is to get out there on talk shows and in front of cameras and say all this.
The mainstream gerontology community are generally a bit conservative – they have vested interests in being successful in publishing papers, they get grants they have worries around peer review, they want tenure, and have a reputation to uphold. Gerontologists hold the keys to public trust – they are considered to be the authorities on aging.
Stephen heads up corporate development for Oisín Biotechnologies. He has served as a business advisor to Oisín since its inception and has served on several biotechnology company advisory boards, specializing in business strategy and capital formation. Prior to Oisín, his career spanned over 15 years in the banking industry where he served as trusted advisor to accredited investors around the globe. Most recently he headed up a specialty alternative investment for a company in San Diego, focusing in tax and insurance strategies for family offices and investment advisors. Stephen is the founder of several ventures in the areas of real estate small manufacturing of novelty gifts and strategic consulting. He serves on the Overlake Hospital’s Pulse Board, assists with Children’s Hospital Guild and is the incoming Chairman at the Columbia Tower Club, a member’s club in Seattle.